| Recruiting patients to clinical trials is an enormous challenge, taking up to 30% of the drug development timeline. For paediatric and rare cancers, the challenge is even greater. This combined with the low incentive for the pharmaceutical industry to develop drugs for smaller patient populations, means too few drug candidates are moving from academia into the clinic.
Non-profit organisations are crucial to meeting this need, but the high cost of clinical trials makes it difficult for them to fund on their own. That’s why, in the past six months, our Centre for Drug Development began partnerships with the Dutch and Norwegian cancer societies to pool resources, expertise and patients, and bring more treatments to underserved patients. |
